Hovig E, Rye P D, Warren D J, Nustad K
Central Laboratory, Norwegian Radium Hospital, Oslo, Norway.
Tumour Biol. 2001 Nov-Dec;22(6):345-7. doi: 10.1159/000050637.
CA 125, a high-molecular-weight mucin, was first defined in 1981 by the monoclonal antibody OC125. Until recently, it has defied many attempts to purify it from a variety of sources, although many research groups have successfully raised antibodies that bind to CA 125. Nevertheless, CA 125 has demonstrated its considerable value as a marker in monitoring patients with ovarian cancer. This year, two research groups have succeeded in cloning the high-molecular-weight mucin CA 125. Their findings are summarized and the significance discussed in light of existing data from the human genome.
CA 125是一种高分子量粘蛋白,于1981年首次由单克隆抗体OC125鉴定。直到最近,尽管许多研究小组已成功制备出与CA 125结合的抗体,但从多种来源纯化CA 125的尝试均未成功。然而,CA 125已证明其作为监测卵巢癌患者的标志物具有重要价值。今年,两个研究小组成功克隆了高分子量粘蛋白CA 125。现将他们的研究结果进行总结,并根据人类基因组的现有数据讨论其意义。